Capital Markets Day: Commercial Execution and Innovation in Obesity Care slide image

Capital Markets Day: Commercial Execution and Innovation in Obesity Care

13 Commercial execution and innovation Obesity care The number of physicans prescribing WegovyⓇ has already surpassed SaxendaⓇ Total number of prescribers has already surpassed SaxendaⓇ Current WegovyⓇ prescribers Prescribers (in 000s) 12 10 8 6 4 35% 48% Prescriber engagement Novo NordiskⓇ Dedicated sales force and medical liaisons • Sales force-250 reps • Call plan targeting ~35k physicians • Medical liaisons providing education Medical education 2 8% 9% 0 Rethink ObesityⓇ Jun 2021 Feb 2022 Nurse practitioner/Physician assistant Primary care physician -SaxendaⓇ -WegovyⓇ Endocrinologist Other TW: Total writers; FTW: First time writers; HCP: Health care providers • • Advance understanding of obesity as a chronic disease Educate providers on evidence- based clinical interventions Communicate impact of treatment on complications and quality of life CMD22 CAPITAL MARKETS DAY
View entire presentation